免疫检查点抑制剂相关结肠炎的研究进展OA北大核心CSTPCD

Immune checkpoint inhibitors(ICIs),including cytotoxic T-lymphocyte-associated protein 4(CTLA-4)inhibitors and programmed cell death receptor 1(PD-1)inhibitors and their ligand 1(PD-L1)inhibitors,have transformed the clinical outcomes of many patients with malignancies.programmed cell death receptor 1(PD-1)inhibitors and their ligand 1(PD-L1)inhibitors have changed the clinical outcomes of many patients with malignan-cies and have become the most important anti-tumor tools available.With the widespread use of immunotherapy,immune-related adverse events(irAEs)induced by ICIs have gradually attracted clinical attention,among which ICI-related colitis has become the most common adverse event in the gastrointestinal system.In this paper,we describe the epidemiology,pathogenesis and clinical management of ICI-related colitis,with the aim of providing reference for clinicians to identify and treat ICI-related colitis in a timely manner.